Taking confidence from CREDENCE and navigating with SONAR: new evidence for reducing renal failure in diabetes
Keywords:CREDENCE, SONAR, renal disease, diabetes, gliflozins, endothelin antagonist
Pervokic V, Jardine MJ, Neal B, et al, for the CREDENCE Trial Investigators. Canaglifloizin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 2019; published online 14 April 2019. https://doi.org/10.1056/NEJMoa1811744
Heerspink HJL , Parving H-H, Andress DL, et al, on behalf of the SONAR Committees and Investigators. Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double blind randomised placebo controlled trial. Lancet 2019;393:1937–47. https://doi.org/10.1016/S0140-6736(19)30772-X
Publish & Transfer of Copyright Agreement
For the mutual benefit and protection of the Author and the Journal Owner/Publisher it is necessary that the Author provides formal written Consent to Publish and Transfer of Copyright before publication of the Work.